A new clinical trial led by the James that utilizes immunotherapy is showing great promise in treating women with a recurrence of endometrial cancer (also called uterine cancer). In this episode, David O’Malley, MD, director of the James Division of Gynecologic Oncology and Co-Director of the Gyn Oncology Phase I Program, describes the trial and its great promise. Previously, “we had limited options and they had significant toxicity,” O’Malley said of women who had recurrent or metastatic endometrial cancer. In this new trial, women were treated with pembrolizumab (marketed as Keytruda) an immunotherapy used to treat several types of cancer and targets the cellular receptors cancer cells use to shield themselves from the body’s immune system. Removing these “blockers allows the immune system to identify and attack” the cancer cells,” O’Malley explains. There were 79 patients in the trial “and 48 percent responded markedly and 14 percent had a complete response and their cancer was completely gone,” O’Malley said.